Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
PTPI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.22
N/A
-6.70
vs -1.70
Q4.22
N/A
-0.66
vs -7.20
Q1.23
N/A
-105.04
vs -0.10
Q2.23
N/A
-1.20
vs -0.90
Q3.23
N/A
-2.31
vs -6.70
Q4.23
+120%
0.13
vs -0.66
Q1.24
N/A
-2.17
vs -105.04
Q2.24
N/A
-0.37
vs -1.20
Q3.24
N/A
-0.53
vs -2.31
Q4.24
N/A
-0.04
vs 0.13
Sales Growth
YoY
Current
Estimates
Q3.22
-168%
-1457732.00 vs 2.1M
Q4.22
+192%
798.1K vs -867160
Q1.23
+2%
2.5M vs 2.5M
Q2.23
-52%
2M vs 4.2M
Q3.23
+215%
1.7M vs -1457732
Q4.23
-146%
-364250.00 vs 798.1K
Q1.24
-45%
1.4M vs 2.5M
Q2.24
-29%
1.4M vs 2M
Q3.24
-6%
1.6M vs 1.7M
Q4.24
+299%
725.4K vs -364250
Return on Equity
QoQ
Q1.23
-1420%
-14.20
vs -0.25
Q2.23
-20%
-0.20
vs -14.20
Q3.23
-66%
-0.66
vs -0.20
Q4.23
+3%
0.03
vs -0.66
Q1.24
-82%
-0.82
vs 0.03
Q2.24
-7%
-0.07
vs -0.82
Q3.24
-71%
-0.71
vs -0.07
Q4.24
+124%
1.24
vs -0.71
Institutionnal Ownership
QoQ
Q4.20
20
20
vs NA
NA
Q1.21
17
17
vs 20
-15%
Q2.21
18
18
vs 17
6%
Q3.21
15
15
vs 18
-17%
Q4.21
21
21
vs 15
40%
Q1.22
19
19
vs 21
-10%
Q2.22
14
14
vs 19
-26%
Q3.22
13
13
vs 14
-7%
accessnewswire.com
9 hours ago
accessnewswire.com
9 hours ago
accesswire.com
9 hours ago
Forecast
655%2025-Revenue
NaN%2025-EPS
49%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.00 ( 5.47%)
Relative Strenght
1
Volume Buzz
-93%
Earning Acce
No
Dist 52w H.
93%Quote Panel
Key Metrics
Relative Strength
PTPI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
